UCSF Researchers Uncover New Pathway for Molecular Cancer Drug Therapies
Researchers have discovered a cellular uptake pathway for larger molecules that delivers cell-permeable drugs efficiently.
![](/sites/default/files/styles/news_card__image/public/fields/field_insert_file/news/drug-molecule.jpg)
University of California San Francisco
Give to UCSFResearchers have discovered a cellular uptake pathway for larger molecules that delivers cell-permeable drugs efficiently.
Through decades of biobanking at UCSF, researchers were able to comprehensively map intra-cellular signaling in the cells of recurrent glioblastoma, identifying novel cell-extrinsic therapeutic targets.
T-cells can be directed to produce cytokine, a powerful anti-cancer component, when they encounter cancer cells. This holds tremendous promise for cancer immunotherapy.
UCSF experts in multiple myeloma and other hematologic malignancies will attend the American Society of Hematology’s (ASH) 64th Annual Meeting and Exposition.
A new sophisticated machine learning technique using a molecular library of commands guides engineered immune cells to seek out and tirelessly kill cancer cells.
UCSF breast cancer experts will present new research and clinical findings at the annual San Antonio Breast Cancer Symposium, the largest and most prestigious breast cancer conference.
Researchers have identified specific immune cells that drive deadly heart inflammation in a small fraction of patients treated with powerful cancer immunotherapy drugs.
E-cigarettes and marijuana have similar harmful effects on the heart as tobacco cigarettes, opening the door to abnormal heart rhythms, reports a team of researchers at UCSF.
A new method of comparing massive numbers of CAR-T cells can determine which is most effective and long-lasting against cancer.
Bacteria in our guts may play a significant role in the metabolism of anti-cancer drugs that are critical for treating colon cancer and other types of cancers.
Immune checkpoint inhibitors (ICIs) used in cancer care can cause myocarditis, a potentially fatal side effect, and it appears that the adverse cardiac effects may disproportionally impact female patients.
A new therapy pulls forward a mutated version of the KRAS protein to help the immune system recognize and destroy cancer cells.
UCSF-led research outlines the comprehensive immune landscape and microbiome of pancreatic cysts as they progress from benign cysts to pancreatic cancer. Their findings could reveal the mechanism of neoplastic progression and provide targets for immunotherapy to inhibit progression or treat invasive disease.
Pregnant women in the U.S. are being exposed to chemicals like melamine, cyanuric acid, and aromatic amines that can increase the risk of cancer and harm child development, according to a study from researchers at UCSF and Johns Hopkins Bloomberg School of Public Health.
T cells used in immunotherapy treatments can get exhausted and shut down by fighting cancer cells and tumors. Using a CRISPR-based edit on these cells’ genomes, researchers at UCSF and Gladstone Institutes have rendered the therapeutic cells more resilient against tumors.
A new UCSF study reports for the first time that significant hearing issues often occur among adult survivors of the most common forms of cancer.
In a groundbreaking finding, a new study led by UCSF found that routine screening for and removal of precancerous anal lesions can significantly reduce the risk of anal cancer, similar to the way cervical cancer is prevented in women.
For many women, breast cancer screening with a three-dimensional imaging technique called digital breast tomosynthesis (DBT) may not offer advantages over digital mammography, but for some it may reduce the chance of an advanced cancer diagnosis, according to a new JAMA study.
Companies claim there’s bad stuff in our homes and bodies, and we should pay to purge it. What’s worth worrying over?
As a worldwide shortage of contrast dye for medical imaging continues, a new UCSF research letter in JAMA quantified strategies to safely reduce dye use in computed tomography (CT) by up to 83%. CT is the most common use for the dye.
UCSF research scientists and statisticians have developed improved biomarker classifications as part of their research results in the I-SPY 2 trial for high-risk breast cancer patients. The new cancer response subtypes reflect responsiveness to drug treatments and are intended to help clinicians be more precise in how they target therapies.
The latest advances in cancer care and research will be showcased at the annual American Society of Clinical Oncology (ASCO) Annual Meeting, the world’s largest clinical cancer meeting.
Nevan Krogan, PhD, director of UCSF’s Quantitative Biosciences Institute, examines in detail the effects of a handful of genes that seem to play an outsize role in a wide array of diseases.
Brain tumor patients survived longer when treated aggressively with surgery, radiation and chemotherapy. Now, a UCSF study underscores the critical role of genomic profiling in diagnosing and grading brain tumors.
UCSF researchers successfully leveraged an FDA-approved drug to halt growth of tumors driven by mutations in the RAS gene, which are famously difficult to treat and account for about one in four cancer deaths.
Mark Moasser, MD, has sorted out why HER2, the protein driving 1 in 5 breast cancers, is so hard to drug. He explains how the findings correct a naive way of envisioning how HER2 is shaped and how it works.